tradingkey.logo

Compass Pathways Successfully Achieves Primary Endpoint In First Phase 3 Trial

ReutersJun 23, 2025 10:31 AM

- Compass Pathways PLC CMPS.O:

  • COMPASS PATHWAYS SUCCESSFULLY ACHIEVES PRIMARY ENDPOINT IN FIRST PHASE 3 TRIAL EVALUATING COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION

  • COMPASS PATHWAYS PLC - COMP360 SHOWS SIGNIFICANT REDUCTION IN SYMPTOM SEVERITY IN PHASE 3 TRIAL

  • COMPASS PATHWAYS PLC - DSMB FINDS NO UNEXPECTED SAFETY ISSUES WITH COMP360

  • COMPASS PATHWAYS PLC - COMP006 TRIAL 26-WEEK DATA EXPECTED IN SECOND HALF OF 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI